Stiefel

Dermatology is finally over!!!!!! Wonder who's going to snatch up the produce line..... Any thoughts?

 

Are you just referring to Zeasorb? That is about the only thing they have left

 

Is Stiefel done worldwide or just in US? Is the office in RTP closing down?

 

I thought Stiefel was staying in RTP for now and then eventually moving to Philly.

 

Have we recouped the $2.9 billion cash + $400 million debt yet?

 

ah…NO. DC took a company that was selling about $ 1 billion a year and made it into a what maybe $ 200 million dollar company. Similar with Advair - $ 5 billion to $ 3 billion. Great work!

Remember it is the fault of "pricing pressures" in the market. LOL.

 

What a great investment. What a POS GSK bought.

 

As a former Stiefel employee: we were doing just fine before the brilliant GSK leadership got their mitts on us. I've worked long enough in this industry to know the Big Pharma effect post acquisition: more lawyers and compliance than sales and marketing. What a horror show: paying the price if the past GSK misdeeds and now being tainted by our connection.

Your cumbersome processes, having meetings to discuss having meetings. So many layers of idiots with creative titles suckling on the GSK teat. This has to be what it's like to work for the US Government. It has to be. It was so fun asking why the sales data was screwed up and waiting a year until GSK could appoint somebody to study the issue, build their team, and slowly work toward cleaning it up. Incredible.

I still think there are a fair amount of sharp sales people but Patient First gave power to the losers who can't sell but love to hit the books.

What a crime.

 

From what I heard Stiefel science was in a bad way before GSK came in. With very few projects in the pipeline and poor science being done (not fully understanding the use of excipients). Steifel needed change and improved marketing, sales, science, rationalisation of locations etc.

 

The amazing thing is that Stiefel survived with Cx going to consumer healthcare and Rx going into R&D in PA. Several of us thought Stiefel would be sold off to help pay down some of GSK's large debt.

Stiefel should get better as more GSK people move in and dilute down the old Stiefel staff who have from reports had limited product development and R&D experience.

 

there is no science in Derm. The model is all about delivery. This si the model for every Derm company.

 

survived? Stiefel is done in the US. All products are no longer promoted and moved to life cycle.
Charlie Stefiel is laughing all the way to the bank. Another great success diedra had her hand in.

 

Many thought after Steifel's poor financial performance last year (witness the bonuses paid in March 2014 compared to other groups like R&D) that they would be sold off.
They are now being, for better or worse, fully integrated into R&D, Consumer Health and the franchises. They are not a standalone group that could easily be sold off but fully integrated. That is a change.
They would not pay millions to relocate the Steifel Rx R&D staff to PA if they did not intend, for at least a few years, to stay in the Stiefel space.

 

From what you heard? Clean out your ears. Stiefel was doing around $450 million in the US when GSK bought the company. Now it is doing around $20 million. So, tell us again as to how Stiefel was in a "bad way" before GSK compared to how it is today.

 

Obviously we placed the smithkline idiots in charge of the franchise

 

What has happened to the Stiefel reps and the managers? Were they redeployed or severance?

 

Yes

 

Is Simon still in charge?

 

No, he will be running the franchises. Of which there will be only 2. Down from the current 5.